Shalabh Singhal

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial

Eric F. Morand, Marilyn C. Pike, Joan T. Merrill et al. · Arthritis & Rheumatology · 2022 · 217 citations · Full text

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

Philip J. Mease, Atul Deodhar, Désirée van der Heijde et al. · Annals of the Rheumatic Diseases · 2022 · 188 citations · Full text

Risk of Major Bleeding with Concomitant Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients Receiving Long‐Term Warfarin Therapy

Deborah DeEugenio, Louis Kolman, Matthew DeCaro et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2007 · 92 citations

LB0004 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

E. Morand, Margaret N. Pike, JT Merrill et al. · Annals of the Rheumatic Diseases · 2022 · 19 citations · Full text

Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin

Amanda M. Farr, Yonghua Jing, Stephen S. Johnston et al. · Hospital Practice · 2015 · 14 citations